Impressive Growth Leads to Expansion at Biotec Services
Biotec Services International, the global provider of temperature-controlled packaging and distribution services for clinical trials, is doubling its capacity with the addition of new processing facilities, following impressive growth.
The UK-headquartered company is expanding into additional operational, packaging and storage facilities on the back of 15% growth in the last year.
As a result of increased client demand, which includes a new contract win worth £5 million, Biotec Services is increasing its controlled room temperature storage by 100 per cent and its cold room storage by 400%. It is also creating a second advanced therapeutic medicinal products (ATMP) facility.
Providing support to hundreds of clinical trial and commercial projects for clients across the world, Biotec Services has built an impressive reputation for its cold chain packaging and distribution services across a full temperature range from controlled ambient down to minus 196 °C.
Dr Fiona Withey, CEO, said: “We have an exciting pipeline of work and an increasing number of Phase III trials with larger storage requirements, which has resulted in a need to expand our temperature controlled packaging and storage facilities.
“Feedback from our recent client survey indicated that refrigerated storage at +2 °C to +8 °C is the range that most suits our partners’ requirements so we are developing our facilities in line with this and also bespoke temperature demands.
“The investment demonstrates our continued commitment to developing innovative solutions to meet our clients’ clinical supplies requirements.”
As part of the company’s strategic growth plans, it has also acquired land adjacent to the current Biotec Services’ facilities, which will be developed in-line with client demands.
Dr Withey, continued: “We have ambitious objectives for the next 3 years as we move towards achieving our vision of becoming the market leader in cold chain clinical trial services, headquartered in the UK with a global presence. We will be looking to continue to develop our services for existing customers and to grow more and more partnerships worldwide, tackling new markets. With these plans in mind, we have secured land adjoining our current facilities to accommodate our future growth.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance